The other is also a phase I/II multicenter, randomized, open label study between high dose IL-2 (3 courses of high dose interleukin 600,000 units/kg administered IV every 8 h on Days 1–5 and Days 15–19, maximum 28 doses) vs. high dose IL-2 (same dose) plus entinostat (5 mg orally given every 2 weeks starting on day 14) in ccRCC (NCT03501381). Here, IL2 is linked to nonpapillary renal cell carcinoma.